Evaluation of Efficacy and Safety of Formoterol in Patients With COPD Compared With Placebo in Patients in Japan, EU (OCEAN)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00628862
First received: January 24, 2008
Last updated: September 25, 2012
Last verified: September 2012
Results First Received: March 19, 2010  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator);   Primary Purpose: Treatment
Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Formoterol Turbuhaler® 4.5mg
Drug: Formoterol Turbuhaler® 9 mg
Drug: Turbuhaler® placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Outpatients, male or female aged ≥ 40 years with moderate to severe chronic obstructive pulmonary disease (COPD). 766 subjects enrolled; 153 excluded: 96 for incorrect enrollment, 17 for adverse events, 32 for voluntary discontinuation, 1 for non-compliance with protocol, 7 for other reasons. 613 were randomised.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Formoterol 4.5 Bid Formoterol 4.5 ug bid
Formoterol 9.0 Bid Formoterol 9.0 ug bid
Placebo Placebo

Participant Flow:   Overall Study
    Formoterol 4.5 Bid     Formoterol 9.0 Bid     Placebo  
STARTED     206 [1]   199 [1]   208 [1]
COMPLETED     195 [1]   182 [1]   186 [1]
NOT COMPLETED     11     17     22  
Adverse Event                 6                 8                 10  
Withdrawal by Subject                 4                 6                 11  
Lost to Follow-up                 0                 2                 1  
Protocol Violation                 1                 0                 0  
COPD Exacerbation                 0                 1                 0  
[1] randomised patients



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Formoterol 4.5 Bid Formoterol 4.5 ug bid
Formoterol 9.0 Bid Formoterol 9.0 ug bid
Placebo Placebo
Total Total of all reporting groups

Baseline Measures
    Formoterol 4.5 Bid     Formoterol 9.0 Bid     Placebo     Total  
Number of Participants  
[units: participants]
  206     199     208     613  
Age  
[units: Years]
Mean ± Standard Deviation
  66.7  ± 9.4     67.2  ± 9.2     66.3  ± 9.7     66.75  ± 9.4  
Gender  
[units: Participants]
       
Female     23     29     22     74  
Male     183     170     186     539  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Forced Expiratory Volume in 1 Second (FEV1; L) 60 Minutes Post-dose   [ Time Frame: from baseline up to 12 weeks ]

2.  Secondary:   Forced Vital Capacity (FVC) 60 Minutes Post-dose   [ Time Frame: from baseline up to 12 weeks ]

3.  Secondary:   FEV1 Pre-dose   [ Time Frame: baseline at week 0 and pre-dose at weeks 4, 8 and 12 ]

4.  Secondary:   FVC Pre-dose   [ Time Frame: baseline at week 0 and pre-dose at weeks 4, 8 and 12 ]

5.  Secondary:   FEV1 5 Minutes Post-dose   [ Time Frame: baseline and 5 minutes anter first dose ]

6.  Secondary:   FVC 5 Minutes Post-dose   [ Time Frame: baseline and 5 minutes anter first dose ]

7.  Secondary:   Change in Peak Expiratory Flow (PEF), Morning   [ Time Frame: run-in period and 12 week ]

8.  Secondary:   Change in Peak Expiratory Flow (PEF), Evening   [ Time Frame: run-in period and 12 week ]

9.  Secondary:   Change in Night-time Awakenings Due to Symptoms   [ Time Frame: run-in period up to 12 weeks ]

10.  Secondary:   Breathlessness   [ Time Frame: run-in period up to 12 weeks ]

11.  Secondary:   Cough   [ Time Frame: run-in period up to 12 weeks ]

12.  Secondary:   Use of Reliever Medication   [ Time Frame: 12 weeks (end of run-in to last visit) ]

13.  Secondary:   St George’s Respiratory Questionnaire (SGRQ)   [ Time Frame: 12 weeks (end of run-in to last visit) ]


  Serious Adverse Events


  Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Gerard Lynch
Organization: AstraZeneca
e-mail: aztrial_results_posting@astrazeneca.com


No publications provided by AstraZeneca

Publications automatically indexed to this study:

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT00628862     History of Changes
Other Study ID Numbers: D5122C00001, EudraCT no 2007-003999-19
Study First Received: January 24, 2008
Results First Received: March 19, 2010
Last Updated: September 25, 2012
Health Authority: Japan: Pharmaceuticals and Medical Devices Agency
Bulgaria: Bulgarian Drug Agency
Romania: National Medicines Agency
Russia: Ministry of Health of the Russian Federation
Ukraine: Ministry of Health